- Home
- AVK vs OVID Comparison
AVK vs OVID Comparison
Compare AVK & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVK | OVID |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.5M | 522.6M |
| IPO Year | 2003 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AVK | OVID |
|---|---|---|
| Price | $12.59 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 136.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $10.77 | $1.05 |
| 52 Week High | $13.28 | $3.11 |
Technical Indicators
Market Signals| Indicator | AVK | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 55.99 |
| Support Level | $12.48 | $2.49 |
| Resistance Level | $12.67 | $2.77 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 34.93 | 71.15 |
Price Performance
Historical ComparisonAbout AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.